Dr.Marty Makary, the Commissioner of the U.S.Food and Drug Administration (FDA), resigned from his position on May 12, 2026, after ongoing disagreements with President Donald Trump.The conflict largely revolved around the approval of flavored vape nicotine products.The Trump administration had been pushing to expand access to these flavored vapes, while Dr.Makary's office issued a memo blocking several flavors from retail authorization.

This disagreement reportedly put him 'on thin ice' with the President, and anonymous sources suggest that the decision to remove him had been planned for several months.Dr.

Makary's tenure at the FDA was marked by significant internal turmoil, including mass layoffs, senior leadership turnover, and policy disputes with lawmakers and pharmaceutical companies.

His approach to regulatory decisions and agency management often clashed with the Trump administration's priorities, creating a contentious atmosphere within the agency.

This resignation marks the fourth high-profile departure from the Trump administration in 2026, highlighting ongoing tensions in regulatory and health policy management under this administration.